Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

Daniele Porru, Enrica Bucchioni, Marcello Macchi, Fabio Leva, Alberto Parmigiani, Davide Barletta, Dimitrios Choussos, Barbara Gardella, Maria Diletta Daccò, Rossella Elena Nappi, Massimo Allegri, Carlo Maria Bianchi, Arsenio Spinillo, Bruno Rovereto

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O'Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalUrogynaecologia International Journal
Volume26
Issue number1
DOIs
Publication statusPublished - 2012

Fingerprint

Interstitial Cystitis
Urinary Bladder
Pain
Omalizumab
Hypersensitivity
Therapeutics

Keywords

  • Anti-IgE treatment
  • Interstitial cystitis/bladder pain syndrome
  • Omalizumab

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Urology

Cite this

Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome. / Porru, Daniele; Bucchioni, Enrica; Macchi, Marcello; Leva, Fabio; Parmigiani, Alberto; Barletta, Davide; Choussos, Dimitrios; Gardella, Barbara; Daccò, Maria Diletta; Nappi, Rossella Elena; Allegri, Massimo; Bianchi, Carlo Maria; Spinillo, Arsenio; Rovereto, Bruno.

In: Urogynaecologia International Journal, Vol. 26, No. 1, 2012, p. 22-25.

Research output: Contribution to journalArticle

@article{a36d660f972b4b7fa3367a8ccabbbe7b,
title = "Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome",
abstract = "The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O'Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.",
keywords = "Anti-IgE treatment, Interstitial cystitis/bladder pain syndrome, Omalizumab",
author = "Daniele Porru and Enrica Bucchioni and Marcello Macchi and Fabio Leva and Alberto Parmigiani and Davide Barletta and Dimitrios Choussos and Barbara Gardella and Dacc{\`o}, {Maria Diletta} and Nappi, {Rossella Elena} and Massimo Allegri and Bianchi, {Carlo Maria} and Arsenio Spinillo and Bruno Rovereto",
year = "2012",
doi = "10.4081/uij.2012.e8",
language = "English",
volume = "26",
pages = "22--25",
journal = "Urogynaecologia International Journal",
issn = "1121-3086",
publisher = "Associato All'USPI - Unione Stampa Periodica Italia",
number = "1",

}

TY - JOUR

T1 - Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

AU - Porru, Daniele

AU - Bucchioni, Enrica

AU - Macchi, Marcello

AU - Leva, Fabio

AU - Parmigiani, Alberto

AU - Barletta, Davide

AU - Choussos, Dimitrios

AU - Gardella, Barbara

AU - Daccò, Maria Diletta

AU - Nappi, Rossella Elena

AU - Allegri, Massimo

AU - Bianchi, Carlo Maria

AU - Spinillo, Arsenio

AU - Rovereto, Bruno

PY - 2012

Y1 - 2012

N2 - The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O'Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

AB - The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O'Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

KW - Anti-IgE treatment

KW - Interstitial cystitis/bladder pain syndrome

KW - Omalizumab

UR - http://www.scopus.com/inward/record.url?scp=84865469021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865469021&partnerID=8YFLogxK

U2 - 10.4081/uij.2012.e8

DO - 10.4081/uij.2012.e8

M3 - Article

AN - SCOPUS:84865469021

VL - 26

SP - 22

EP - 25

JO - Urogynaecologia International Journal

JF - Urogynaecologia International Journal

SN - 1121-3086

IS - 1

ER -